This story has been updated to include comments from the company's earnings call.

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market Thursday that its first quarter revenues fell 7 percent to $305,000 from $328,000 in Q1 2013.

Vermillion posted product sales of $191,000, down 11 percent from $214,000 year over year. Those sales are based on 3,817 OVA1 ovarian cancer tests performed in Q1 versus 4,274 tests performed in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.